Samuel Waxman, MD Email Samuel Waxman
-
- Positions
- DISTINGUISHED SERVICE PROFESSOR | Medicine, Hematology and Medical Oncology
- DISTINGUISHED SERVICE PROFESSOR | Oncological Sciences
-
- Specialty
- Hematology-Oncology
-
- Language
- English
-
- Hospital Affiliation
- The Mount Sinai Hospital
-
- Phone
- 212-289-2828212-289-2828
A valued member of Mount Sinai's faculty for over 30 years, Samuel Waxman is the Zena and Michael A. Wiener Professor of Medicine (Cancer). Dr. Waxman currently holds a variety of positions, including Professor Consultant, Shanghai Second Medical University, Head, Rochelle Belfer Chemotherapy Foundation Laboratory in the Division of Medical Oncology at The Mount Sinai Medical Center, and Medical Director, Samuel Waxman Cancer Research Foundation.
Certifications
Hematology
American Board of Internal Medicine
Education
MD, S.U.N.Y., Health Science Center
Residency, Internal Medicine
Mount Sinai Hospital
Residency, Internal Medicine
Mount Sinai Hospital
Fellowship, Hematology
Mount Sinai Hospital
Language
English
Ferrari AC, Waxman S. Differentiation Agents in Cancer Therapy. In: Pinedo HM, Longo DL, Chabner BA, editors. Cancer Chemotherapy and Biological Response Modifiers Annual 15. B.V., Elsevier Science; 1994.
Jing Y, Zhang J, Bleiweiss IB, Waxman S, Zelent A, Mira-Y-Lopez R . Defective expression of cellular retinol binding protein type I and retinoic acid receptors a2, b2, and g2 in human breast cancer cells. FASEB J 1996; 10: 1064-1070.
Jing Y, Waxman S, Mira-Y-Lopez R . The cellular retinoic acid binding protein II is a positive regulator of retinoic acid signaling in breast cancer cells. Cancer Res 1997; 57: 1668-1672.
Dai J, Weinberg R, Waxman S, Jing Y. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 1999; 93: 268-277.
Waxman S. Differentiation therapy in acute myelogenous leukemia (non-APL). Leukemia 2000; 14: 491-496.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Waxman did not report having any of the following types of financial relationships with industry during 2017 and/or 2018: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website.
Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.